- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02219412
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
An Open Label, Two Arms, Randomized Controlled Pilot Study Comparing the Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable Coronary Artery Disease Treated With Ticagrelor Monotherapy or Ticagrelor and Asprin
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a randomized, open labeled, active-controlled pilot study to estimate the difference of arachidonic acid induced platelet aggregation rate between ticagrelor monotherapy and aspirin/ticagrelor dual-therapy in patients with stable coronary heart disease. The anticipated duration of the study is approximately 9 months, including an anticipated enrolment period of 8 months and follow-up period of 4weeks.
Patients with documented coronary heart disease and currently receiving dual-antiplatelet therapy with standard dose aspirin and clopidogrel will be enrolled from the study site. For patients post acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), they must be on dual-antiplatelet therapy for at least 12 months to be eligible for the study.
The study plan, including enrolment/randomization and follow-up visits, is outlined in Table 1. Eligible patients will enter a washout phase with ticagrelor for 2 weeks. Then they will be randomized to take either ticagrelor alone or aspirin/ticagrelor for 14 days. The efficacy evaluation will be done at 7 and 14days after randomization. The primary efficacy parameter is the rate of arachidonic acid induced platelet aggregation after 14 days of treatment. All patients will be treated to standards of care for coronary heart disease secondary prevention.
Visit 0 (Screening and Enrollment, 0 day) All potentially eligible patients will undergo a screening visit following their signed informed consent.
Following an 8-hour fast, the patients will have screening evaluations performed. Demography, medical history, and concomitant medication will be recorded. A physical examination and vital signs(pulse and BP), height and weight, as well as blood sampling for laboratory assessments of complete blood count (CBC) with differential, serum creatinine, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and AA, adenosine diphosphate (ADP) and collagen induced platelet aggregation rate will be done. Standard 12-lead electrocardiogram (ECG) readings will be recorded.
Patients meeting all inclusion criteria and with no exclusion criteria will be enrolled. Patients will receive ticagrelor mono-therapy from the evening for 14 days. IP will be dispensed.
Visit 1 (Randomization, 14 days) Suspected adverse events (AEs) will be recorded. A physical examination and vital signs (pulse and BP), as well as blood sampling for laboratory assessments of AA, ADP and collagen induced platelet aggregation rate and serum thromboxane B2 concentration will be done.
Patients should be told to take ticagrelor in the morning of Visit 1. Patients will be randomized in a 1:1 ratio to receive either ticagrelor mono-therapy or aspirin/ticagrelor dual-therapy. Investigational product (IP) will be returned and compliance assessed and new bottles of IP will be dispensed according to randomized groups.
Visit 2 (21 days) Suspected AEs will be recorded. Vital signs (pulse and BP) as well as blood sampling for laboratory assessments of AA, ADP and collagen induced platelet aggregation rate will be done.
Visit 3 (End of treatment, 28 days) Suspected AEs will be recorded. Vital signs (pulse and BP) as well as blood sampling for laboratory assessments of CBC with differential, Scr, ALT and AST, AA, ADP and collagen induced platelet aggregation rate will be done. IP will be returned and compliance assessed. Instructions for medication after study will be given to patients at this time.
For patients who prematurely discontinued the randomized treatment, a complete end of treatment visit will be preferred.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 100034
- Peking University First Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures.
- Aged >18 years.
- Documented stable coronary artery disease.
- Currently receiving dual-antiplatelet therapy with aspirin 100mg/d and clopidogrel 75mg/d.
Exclusion Criteria:
- History of acute coronary syndrome within 12 months of screening.
- History of percutaneous coronary intervention within 12 months of screening.
- Any indication (eg, atrial fibrillation,prosthetic heart valve, or coronary stent) for antithrombotic therapy(eg, warfarin, clopidogrel, or aspirin dose other than 75 to 100 mg/during the study period).
- AA induced platelet aggregation rate >20% on aspirin+clopidogrel measured by light transmission platelet aggregation test with the past 3 months.
- Congestive heart failure or left ventricular ejection fraction <35%.
- Forced expiratory volume in the first second forced vital capacity below the lower limits of normal.
- Bleeding diathesis or severe pulmonary disease.
- Active pathological bleeding.
- History of intracranial hemorrhage.
- Hypersensitivity to ticagrelor or any of the excipients.
- Severe hepatic impairment.
- Pregnancy.
- Current smoking.
- Platelet count <100 000/mm3 or hemoglobin <10 g/dL.
- HemoglobinA1c >10%.
- History of drug addiction or alcohol abuse in the past 2 years.
- Need for nonsteroidal anti-inflammatory drug.
- Creatinine clearance<30 mL/min.
- Concomitant therapy with moderate or strong cytochrome P450 3A inhibitors, substrates, or strong cytochrome P450 3A inducers.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: ticagrelor mono-therapy
Take ticagrelor 90 mg Bid for 2 weeks.
|
90 mg bid for 2 weeks
Andre navn:
|
Aktiv komparator: aspirin/ticagrelor dual-therapy
Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
|
90 mg bid for 2 weeks
Andre navn:
100mg Qd for 2 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The rate of AA induced platelet aggregation
Tidsramme: Day 14 after randomization
|
The rate of AA induced platelet aggregation will be measured at day 14 after randomization.
|
Day 14 after randomization
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The rate of ADP induced platelet aggregation
Tidsramme: Day 7 and day 14 after randomization
|
The rate of ADP induced platelet aggregation will be measured at day 7 and day 14 after randomization.
|
Day 7 and day 14 after randomization
|
The rate of collagen induced platelet aggregation
Tidsramme: Day 7 and day 14 after randomization
|
The rate of d collagen induced platelet aggregation will be measured at day 7 and day 14 after randomization.
|
Day 7 and day 14 after randomization
|
The serum concentration of Thromboxane B2
Tidsramme: Day 7 and day 14 after randomization
|
The serum concentration of Thromboxane B2 will be measured at day7 and day 14 after randomization
|
Day 7 and day 14 after randomization
|
The rate of AA induced platelet aggregation
Tidsramme: Day 7 after randomization
|
The rate of collagen induced platelet aggregation will be measured on Day 7 after randomization
|
Day 7 after randomization
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Huo Yong, MD, Peking University First Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Arteriosklerose
- Arterielle okklusive sykdommer
- Hjertesykdommer
- Koronararteriesykdom
- Myokardiskemi
- Koronar sykdom
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystemet
- Enzymhemmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Fibrinolytiske midler
- Fibrinmodulerende midler
- Blodplateaggregasjonshemmere
- Syklooksygenase-hemmere
- Antipyretika
- Purinergiske P2Y-reseptorantagonister
- Purinergiske P2-reseptorantagonister
- Purinergiske antagonister
- Purinergiske midler
- Aspirin
- Ticagrelor
Andre studie-ID-numre
- ISSBRIL0235
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronar hjertesykdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
Region SkanePåmelding etter invitasjonHjertesvikt New York Heart Association (NYHA) klasse II | Hjertesvikt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbeidspartnereHar ikke rekruttert ennåHjertesvikt, systolisk | Hjertesvikt med redusert utkastningsfraksjon | Hjertesvikt New York Heart Association Klasse IV | Hjertesvikt New York Heart Association klasse IIIPolen
-
Medtronic CardiovascularFullførtArteriosclerosis of coronary artery bypass graftCanada, Forente stater
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
Luigi Sacco University HospitalIRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Padova; Università degli Studi di Ferrara og andre samarbeidspartnereRekrutteringAtrieflimmer | Block Complete HeartItalia, Belgia, Sveits
-
University of WashingtonAmerican Heart AssociationFullførtHjertesvikt, Kongestiv | Mitokondriell endring | Hjertesvikt New York Heart Association Klasse IVForente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
William Beaumont HospitalsFullførtKoronararteriesykdom | Arteriosclerosis of coronary artery bypass graftForente stater
Kliniske studier på ticagrelor
-
Federico II UniversityAdvicePharma GroupFullførtHjerteinfarkt | Koronararteriesykdom | Akutt koronarsyndrom | STEMI | NSTEMIItalia
-
Collegium Medicum w BydgoszczyFullført
-
University of FloridaFullført
-
AstraZenecaParexelFullført
-
University of FloridaAstraZenecaFullført
-
University of FloridaThe Medicines CompanyFullførtKoronararteriesykdomForente stater
-
Centro Hospitalario La ConcepcionRekruttering
-
Sheba Medical CenterFullførtST Elevation Hjerteinfarkt | Akutte koronare syndromerIsrael
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationFullførtAkutt koronarsyndrom | Bivirkning på blodplatehemmende middelItalia, Hellas
-
Bio-innova Co., LtdHar ikke rekruttert ennå